Purpose: Interleukin (IL)-6 promotes tumor growth and signal transduction via both its membrane-bound (CD126) and soluble receptors (sCD126). We aimed to study whether the levels of CD126 expression in chronic lymphocytic leukemic (CLL) cells can predict in vitro and in vivo treatment response.
Translational Relevance
Increased levels of both IL-6 and sCD126 in a variety of cancers are associated with an aggressive disease course and poor prognosis. However, the role of membranebound CD126 and its clinical impact are poorly defined. The current work shows that CLL B-cells express higher levels of CD126 compared with normal B-cells. Higher levels of CD126 significantly correlate with poor treatment response in vitro and in vivo. Tocilizumab, an anti-CD126 antibody, is currently used for the clinical treatment of rheumatoid arthritis. We found that combined treatment of Tocilizumab with chemotherapeuty can overcome chemoresistant of CLL cells, with the greatest effect seen in CLL cases with greatest CD126 expression. CD126 expression could be used
Introduction
Chronic lymphocytic leukemia (CLL) is a highly variable disease and the clinical outcomes are significantly different in individual patients: some patients will live for decades and never require treatment, while others have aggressive disease require treatment at initial presentation (1) . Although the standard treatment includes firstline chemo-immunotherapy approaches, which are associated with a prolonged survival, effective therapies for the more frail elderly patients or those who relapse after previous treatment are urgently needed (2) . CLL prognostication at diagnosis is possible with clinical and biological parameters, such as deletions at chromosome 17p or 11q (3), absence of mutations in the immunoglobulin heavy chain gene (IgHV) (4, 5) , expression of protein tyrosine kinase zeta-associated protein 70 (ZAP-70) (6) the cell surface glycoprotein CD38 (7) , and advanced clinical stage (Binet stage B/C) (8) . Serum IL-6 levels have also been correlated with clinical outcome in CLL, with higher levels of IL-6 associated with a worse prognosis (9) ; similar results have been found in other cancers (10, 11) . Although IL-6 is elevated in the serum of humans suffering from breast, prostate, lung, liver and colon cancer, raised serum IL-6 is also seen in a wide variety of non-malignant diseases (12) .
IL-6 is a multi-function cytokine that is produced by a variety of cell types, including T-cells, B-cells, dendritic cells, macrophages, fibroblasts, endothelial cells, monocytes and keratinocytes (13, 14) . However, the IL-6 membrane-bound receptor, CD126, is expressed only on normal hepatocytes, CD4+ or CD8+ T-cells (15) , certain inflammatory cells, and some cancer cells (16, 17) . If cells do not express sufficient cell-surface CD126, signal transduction can still occur via the IL-6 trans-signaling pathway when IL-6 binds with the soluble form of CD126 (15) .
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Materials and Methods

Patients, cell separation and culture
The protocol was approved by the National Research Ethics Service, East London, and the City HA Local Research Ethical Committee for in vitro studies on blood samples from CLL patients. 58 patients were enrolled in this study and all the cases were either untreated (n=20) or had not received chemotherapy or steroids for over 6 months (Supplementary Table 1 ). Peripheral blood was obtained after written informed consent from patients with CLL in accordance with the Declaration of Helsinki. After informed consent, control blood samples were taken from normal health donors. Peripheral blood mononuclear cells (PBMC) were isolated by densitygradient centrifugation over Ficoll-Paque (GE Healthcare), the cells were used immediately or cultured in complete RPMI-1460 containing 10% fetal calf serum, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin (Sigma) for the further experiments. The normal B lymphocytes from health donor were CD19 positive selection by a column purification system with anti-CD19 beads (Milteny Biotec, Bergish-Gladbach, Germany) (18), the purified CD19+ normal B lymphocytes were stored in liquid nitrogen.
Antibody and reagents
Anti-IL6R antibody (Tocilizumab) was kindly donated by Chugai Pharmaceutical Co Ltd, Japan. The antibodies of p-STAT3 (phospho-STAT3-Ser-727), Mcl-1, and STAT3 were purchased from Cell Signalling Technology; Bcl-2, Bcl-xL, Bax, p27, CDK2 and cyclin E were bought from Santa Cruz; β-actin was purchased from Sigma.
Measurement of membrane-bound IL-6 receptor CD126
Treatment and cell death assays
Measurement of autocrine IL-6
CLL cells were isolated immediately after phlebotomy and used post-ficoll as PBMC.
If greater than 95% of cells were CD19+, but if not, B-CLL cells were purified using a
CD19
+ cell isolation kit (MiltenyiBiotec, Bergish-Gladbach, Germany), with a purity of >97%. 5×10 6 /ml cells were cultured in RPMI-1640 medium at 37°C in a humidified incubator with 5% CO 2 . The supernatants were stored at -80°C until assayed for IL-6
by ELISA, according to the manufacturer's instructions (R&D systems, Abingdon, UK).
Western blotting
Immuno-precipitation
Immuno-precipitation was performed using Dynabeads protein A (Invitrogen). Transfection efficiency and cell death were determined by flow cytometry after transfection with PMAX-GFP plasmid for 24 hours. Protein expression was determined after 24 hours transfection (27).
Statistical analysis
Research.
on July 
Results
CD126 expression on CLL cells correlates with STAT3 activity and ZAP70 positivity
The levels of CD126 expression in CLL and its prognostic impact are unknown. We investigated CD126 expression on 58 fresh CLL samples. The clinical characteristics of the patients are shown in Supplementary Table 1 . Membrane-bound CD126 expression on normal B-cells was negative or very low (Mean=1.7%, range from 0 to 6.3%). However, all cases of CLL cells has surface CD126 expression, although was highly variable in 58 CLL cases (Mean=20.1%, range from 4.5% to 59%) ( Figure 1A and Supplementary Figure 1A 
Blocking CD126 with Tocilizumab induces cell cycle redistribution in CLL cells
CLL remains incurable and this is partly attributable to cells being in the G0 phase of the cell cycle and having high levels of anti-apoptotic Bcl-2 family proteins (30). it was previously reported that IL-6-mediated G0/G1 cell cycle arrest is through JAK2/STAT3 pathway (31). Ki67 is a cellular maker for proliferation, which is expressed throughout the cell cycle, except for G0 phase (32). In CLL cells, both Ki67 and nuclear DNA staining demonstrated that most cells were in G0 phase (Figure 3 A), a factor contributing to chemoresistance (33) . Treatment with the humanized anti-CD126 blocking antibody, Tocilizumab, led to a marked increase in G1 phase cells, as detected by Ki67 positivity, without further progression through the cell cycle to G2/M/S phases (Figure 3 A, B) , as detected by Ki67 positivity, without further progression through the cell cycle to G2/M/S phases (Figure 3 A, upper Research. Figure 6) , whereas there was a highly statistically significant direct correlation with CD126 expression (P<0.0001, Figure 4 E). Collectively, these data indicate that combination of Tocilizumab with chemotherapeutic drugs can overcome chemoresistance of CLL cells with higher (more than 10%) expression of CD126. In CLL cases with CD126 expression less than 10%, the average increase of apoptosis by Tocilizumab was 3.6%, as compared to a mean increase of 13% in those cases with great than 10% CD126 expression (P<0.001, Figure 4 
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Rawstron (F) Tocilizumab increased CBL-induced apoptosis in CLL divided by surface CD126 expression of less than 10% (n=13) or more than 10% (n=20, * * * P<0.001).
